Some individuals may opt for compounded semaglutide due to the need for customization, availability during shortages, or the perception that it may be more affordable than FDA-approved options
Measures of cardiometabolic health were expected to return to pre-treatment levels even sooner, within approximately 1.4 years of stopping the drugs
Peptides have become focal points in diverse research arenas owing to their versatility and potential advantages
L.HanX.LewisS
Hybrid RD plus AI models help providers extend service capacity
According to the FDA's official guidance (updated April 2026 at fda.gov), the semaglutide injection shortage was resolved on February 21, 2025, and the transitional exemption windows for compounders operating under the shortage exemption subsequently ended - for 503A pharmacies by April 22, 2025, and for 503B outsourcing facilities by May 22, 2025